<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7419580\results\search\drug\results.xml">
  <result pre="available that reference secondary infections showed that most clinicians prescribed" exact="meropenem" post="and linezolid to children with a rate of prophylactic"/>
  <result pre="reference secondary infections showed that most clinicians prescribed meropenem and" exact="linezolid" post="to children with a rate of prophylactic treatment between"/>
  <result pre="commonly used antibiotics were moxifloxacin (n = 452, 39.2%) and" exact="azithromycin" post="(n = 294, 30.7%). Others include ceftriaxone, vancomycin, cefepime,"/>
  <result pre="maxipime, azithromycin, amoxicillin-clavulanate, cefoperazone/sulbactam, quinolone plus azithromycin, levofloxacin, moxifloxacin, and" exact="ceftriaxone" post="plus azithromycin, and most commonly azithromycin (n = 206,"/>
  <result pre="azithromycin, levofloxacin, moxifloxacin, and ceftriaxone plus azithromycin, and most commonly" exact="azithromycin" post="(n = 206, 74.6%). Of the four studies that"/>
  <result pre="in three studies, administering amoxicillin-clavulanate, clarithromycin, azithromycin, levofloxacin, moxifloxacin and" exact="ceftriaxone" post="plus azithromycin (47, 49, 51). In total, 12 patients"/>
  <result pre="studies, administering amoxicillin-clavulanate, clarithromycin, azithromycin, levofloxacin, moxifloxacin and ceftriaxone plus" exact="azithromycin" post="(47, 49, 51). In total, 12 patients out of"/>
  <result pre="Sixty eight patients were treated with the antibiotics piperacillin-tazobactam, azithromycin," exact="ceftriaxone" post="and trimethoprim- sulfamethoxazole, levofloxacin, imipenem and other broad-spectrum antibiotics"/>
  <result pre="(96.6%) (65â€&quot;67, 71, 72). The most commonly used antibiotics were" exact="vancomycin" post="(n = 317, 46.2%) and imipenem/meropenem (n = 243,"/>
  <result pre="= 243, 54.7%). Others were azithromycin, ceftriaxone, cephalosporin, piperacillin-tazobactam, linezolid," exact="vancomycin" post="plus cefepime, vancomycin plus meropenem, clarithromycin, levofloxacin and dicloxacillin."/>
  <result pre="Others were azithromycin, ceftriaxone, cephalosporin, piperacillin-tazobactam, linezolid, vancomycin plus cefepime," exact="vancomycin" post="plus meropenem, clarithromycin, levofloxacin and dicloxacillin. In total, 223"/>
  <result pre="cephalosporin, piperacillin-tazobactam, linezolid, vancomycin plus cefepime, vancomycin plus meropenem, clarithromycin," exact="levofloxacin" post="and dicloxacillin. In total, 223 patients of 910 (24.5%)"/>
  <result pre="one of the studies reported the use of azithromycin, vancomycin," exact="ceftriaxone" post="and cephalosporin (65). In general, all eight case studies"/>
  <result pre="multicenter descriptive study. Clin Infect Dis. (2020) 29:ciaa19910.1093/cid/ciaa199 35.GautretPLagierJCParolaPMeddebLMailheMDoudierBet al.." exact="Hydroxychloroquine" post="and azithromycin as a treatment of COVID-19: results of"/>
  <result pre="study. Clin Infect Dis. (2020) 29:ciaa19910.1093/cid/ciaa199 35.GautretPLagierJCParolaPMeddebLMailheMDoudierBet al.. Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
  <result pre="syndrome coronavirus infection. Ann Intern Med. (2014) 160:389â€&quot;97. 10.7326/M13-248624474051 56.Al-TawfiqJAMomattinHDibJMemishZA." exact="Ribavirin" post="and interferon therapy in patients infected with the middle"/>
 </snippets>
</snippetsTree>
